With a new study of Independence Blue Cross members, evidence on the effectiveness of the patient-centered medical home is swinging back towards the positive.
With a new study of Independence Blue Cross members, evidence on the effectiveness of the patient-centered medical home is swinging back towards the positive.
Of 700 IBC members with multiple chronic conditions treated in patient-centered medical home practices, those with the highest-risk had “significantly reduced costs and utilization” compared to those with analogous health problems treated in regular practices, a study published in the American Journal of Managed Care found.
Those findings deviate a bit from a recent Rand Corp. evaluation of a large PCMH pilot in southeastern Pennsylvania, where little correlation between PCMHs and quality and cost was detected in a three-year analysis.
The new findings are likely to fuel more debate over the actual and perceived benefits of the PCMH, while helping create a foundation of evidence that also help tailor the way the model is used.
Read the full story here: http://bit.ly/1lm1jWx
Source: Healthcare Payer News
FDA Approves bluebird bio's Lovo-Cel Gene Therapy for Sickle Cell Disease
December 10th 2023The decision was supported by efficacy data from 36 patients from the ongoing phase 1/2 HGB-206 trial (NCT02140554) and 2 patients in the phase 3 HGB-210 trial (NCT04293185). It was the second approval from FDA for a gene therapy for sickle cell disease.
Read More